aibioDaiichi Sankyo Company
Daiichi Sankyo is a Japanese drugmaker focused on cancer, best known for the antibody-drug conjugates Enhertu and Datroway it sells with AstraZeneca.
- Ticker
- 4568
- Listing
- TSE, Japan
- Next date
- October 23-27, 2026
- Chief executive
- Hiroyuki Okuzawa
Desk view · Opinion · Updated Oct 22, 2026
Daiichi Sankyo's ADC engine grows fast but leans on Enhertu
Daiichi Sankyo's ADC platform is producing fast revenue growth and a steady flow of breast cancer approvals. Lung cancer is the next test, and 2026 brought a positive Enhertu trial alongside the I-DXd withdrawal. Manufacturing commitments made at peak expectations are a cost of any further pipeline setbacks.
Read the full desk viewaibio.space Investor Rank · Opinion
8/10 Positive view
The Enhertu-led ADC platform is growing revenue fast with breast cancer approvals, while the I-DXd withdrawal and heavy Enhertu concentration temper the lung cancer case.
- Technology
- 2/2
- Odds
- 1/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven ADC platform. Enhertu grew 48.9% in Q1 FY2026 and won two US early breast cancer approvals in May 2026.
- Odds
- Strong in breast, mixed in lung. DESTINY-Lung04 met its PFS goal, but the I-DXd small cell lung cancer filing was withdrawn in September 2026.
- Balance sheet
- Solid. Cash was JPY 637.9 billion at June 30, 2026, against JPY 500.0 billion of non-current bonds and borrowings.
- Main risk
- Concentration and supply commitments. Enhertu is about 42% of revenue, and CMO purchase minimums cost JPY 75.7 billion in fiscal 2025.
- Watch next
- ESMO and AVANZAR. ESMO runs October 23 to 27, 2026, and the AVANZAR readout is due in the second half of calendar 2026.
Top news on Daiichi
Questions investors ask
What is aibio.space's Investor Rank for Daiichi Sankyo Company?
8 out of 10, our positive view. The Enhertu-led ADC platform is growing revenue fast with breast cancer approvals, while the I-DXd withdrawal and heavy Enhertu concentration temper the lung cancer case. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Who is the CEO of Daiichi Sankyo?
Hiroyuki Okuzawa is president and CEO of Daiichi Sankyo. He was quoted in that role in the company's August 24, 2026 announcement naming Ken Keller chief commercialization officer. Source
Why was the ifinatamab deruxtecan BLA withdrawn?
Daiichi Sankyo and MSD withdrew the US application in September 2026 after the FDA said data including the phase 2 IDeate-Lung01 trial did not satisfy requirements for accelerated approval in previously treated ES-SCLC. The phase 3 IDeate-Lung02 trial continues. Source
How much did Enhertu sell in the latest quarter?
Enhertu revenue, including milestone payments, was JPY 239.8 billion in the April to June 2026 quarter, up 48.9%. Total company revenue was JPY 574.7 billion. Source
What is Daiichi Sankyo's FY2026 guidance?
On July 31, 2026 Daiichi Sankyo raised its fiscal 2026 forecast to revenue of JPY 2.34 trillion and operating profit of JPY 320.0 billion, from JPY 2.28 trillion and JPY 315.0 billion. Source
What were the DESTINY-Lung04 results?
Enhertu cut the risk of progression or death by 37% versus pembrolizumab plus chemotherapy in first-line HER2-mutant NSCLC, with median PFS of 14.3 versus 8.3 months. Overall survival was 46.9% mature with no observed benefit. Source
Legal and investor matters
- Litigation
Tokyo court dismisses NTK's JPY 203 billion damages claim against Daiichi Sankyo
Daiichi Sankyo announced that on September 10, 2026 the Tokyo District Court dismissed all claims in a lawsuit by Northern TK Venture (NTK), an indirect subsidiary of IHH Healthcare, against it. NTK filed the suit on October 16, 2023 and later expanded its damages claim to JPY 203,301,807,840. NTK alleged that Daiichi Sankyo interfered with its tender offer for Fortis Healthcare. Daiichi Sankyo says the judgment will have no impact on its financial results and that it will continue to assert its position if NTK appeals.
- Litigation
Daiichi Sankyo says Seagen patent dispute is concluded after review deadlines pass
Daiichi Sankyo announced on March 10, 2026 that its patent dispute with Seagen has concluded. The U.S. Court of Appeals for the Federal Circuit ruled on December 2, 2025 that Seagen's '039 patent was invalid and vacated the Texas infringement judgment and damages award against Daiichi Sankyo. The deadlines for the parties to seek review of the decisions passed on March 2, 2026.
- Litigation
Federal Circuit vacates Seagen infringement judgment against Daiichi Sankyo
On December 2, 2025 the U.S. Court of Appeals for the Federal Circuit reversed an Eastern District of Texas decision that had found Seagen's '039 patent not invalid. It then vacated the related infringement judgment and damages award against Daiichi Sankyo. It also dismissed as moot Seagen's appeal of the January 2024 Patent Office decision that invalidated the challenged claims. Daiichi Sankyo announced the rulings on December 3, 2025.
- Litigation
NTK moves to expand damages claim against Daiichi Sankyo to JPY 203 billion
Daiichi Sankyo said on May 22, 2025 that Northern TK Venture (NTK), an indirect subsidiary of IHH Healthcare, filed a motion on May 9, 2025 to expand its damages claim in the Tokyo District Court. The suit was filed October 16, 2023 and first sought JPY 20 billion. The expanded claim is JPY 203,301,807,840. Daiichi Sankyo said it believes NTK's claims are without merit and would continue to defend its position. On September 10, 2026 the Tokyo District Court dismissed all of NTK's claims, according to Daiichi Sankyo's later announcement.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Enhertu (trastuzumab deruxtecan) | First-line HER2-mutant non-small cell lung cancer | Phase 3 DESTINY-Lung04 met its primary PFS endpoint; presented at WCLC on September 14, 2026 Source |
| Ifinatamab deruxtecan (I-DXd) | Relapsed extensive-stage small cell lung cancer | US accelerated approval BLA withdrawn Sept 2026; phase 3 IDeate-Lung02 enrolling Source |
| Datroway (datopotamab deruxtecan) | First-line non-squamous NSCLC without actionable alterations (AVANZAR) | Phase 3, readout expected CY2026 H2 Source |
| Datroway | EGFR-mutated NSCLC after osimertinib (TROPION-Lung15) | Phase 3, readout expected FY2026 H2 Source |
| Raludotatug deruxtecan (R-DXd) | Platinum-resistant ovarian cancer | Phase 2/3 REJOICE-Ovarian01; update at ESMO 2026 Source |
Stock chart
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction